SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) today announced that it obtained regulatory approval from the Ministry ...

In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The needle-free injection system market is expected to register a CAGR of approx. 13% over the period of 2022-2028. Needle-free injection technology (NFIT) refers to a wide range of drug delivery ...

Sylentis, a wholly-owned subsidiary of Spanish drugmaker PharmaMar (MSE: PHM), announced top-line results from the SYL1801-II ...

This retrospective case series involved a review of medical records at a single tertiary care center. Charbel Issa and ...

Shorter needles are safer to avoid going into the muscle. The International Scientific Advisory Board for the Third Injection Technique Workshop states that there is no medical reason to use a ...

The lens is gently moved medially to allow the needle to reach the injection site. Resistance felt during needle advancement indicates successful penetration of the retina into the subretinal stroma.

Yeoh said hydrodissection continues to be important because of more complications seen from lens touch or needle-stick cataracts caused by intravitreal injections and posterior capsular tears ...